
Suspected Chinese bioterrorists smuggled dangerous agent into US in boots, officials say
One of the two Chinese nationals arrested for allegedly smuggling a toxic crop-killing pathogen, which also has devastating health effects on humans, stuffed the noxious fungus into her boots while entering the United States in 2022, documents show.
According to an arrest affidavit for University of Michigan post-doctoral research fellow Yunqing Jian and her boyfriend, Zunyong Liu, Jian first brought Fusarium graminearum, described as a "potential agroterrorism weapon" in scientific literature, in August 2022.
A transcribed WeChat conversation between Jian and Liu shows Liu instructing Jian on how to smuggle the fungus, according to the affidavit.
Liu: "Teacher Liang's seeds must be placed well."
Jian: "Where to put it? I only have one pair of shoes. The insole cannot be pulled off."
Liu: "Did you bring just one pair of shoes?"
Jian: "3 pair, wear one pair."
Liu: "Where did the seeds get put? In the tube?"
Jian: "I put them in my Martin boots… in a small bag. The ziplock bag. Very small."
Liu: "That's good… Just put it in your shoes."
Jian: "I stuffed them in the shoes."
Fusarium graminearum creates "head blight," a disease of wheat, barley, maize and rice, and "is responsible for billions of dollars in economic losses worldwide each year," according to the Department of Justice.
It is also toxic to humans, and can cause vomiting, liver damage, and "reproductive defects in humans and livestock."
The affidavit, which said Jian has been attempting to smuggle the pathogen into the United States since she began post-doctoral studies funded by China in 2022, also accuses Jian of asking a third party to send her Fusarium graminearum in January 2024.
"There are usually no problems," Jian said in a message to the third person. "Rest assured. I have mailed these before."
That third person allegedly shipped the package, and hid the samples in a statistics textbook. The package was intercepted before it arrived.
Jian is accused of lying on a student visa application about what exactly she planned to study in the United States.
The latest smuggling attempt took place in July 2024, when Liu entered the United States at the Detroit Metropolitan Airport on a tourist visa under the guise of visiting his girlfriend, Jian, authorities said.
U.S. Customs and Border Protection (CBP) flagged Liu upon his arrival, searched his luggage and conducted an interview.
The luggage search "revealed a wad of tissues crumpled up in a small pocket in Liu's backpack," according to the affidavit.
"The tissues concealed a note in Chinese, a round piece of filter paper with a series of circles drawn on it, and four clear plastic baggies with small clumps of reddish plant material inside," the affidavit continues.
An FBI laboratory test found that the filter paper contained Fusarium graminearum, and the baggies of material contained fibrous material that was infected with Fusarium graminearum, authorities said.
"In addition, the laboratory identified 10 separate samples from the filter paper," the affidavit says. "Each sample had a hand drawn circle around it, and each circle was labeled with a code containing letters and/or numbers. The sample labeled '06172' was identified by the FBI laboratory to contain the DNA sequence for Fusarium graminearum."
Liu initially denied knowingly putting the pathogen in his bag, but later admitted to doing it intentionally, authorities said.
He allegedly revealed his entire scheme to the investigators, including telling them that he planned to use the same laboratory that Jian used at the University of Michigan to conduct research. He said that some days during his visit, the lab would be open for use, according to the affidavit, and other days, Jian planned to let him in.
Jian and Liu have been charged with conspiracy, smuggling goods into the United States, false statements and visa fraud.
"This case is a sobering reminder that the Chinese Communist Party continues to deploy operatives and researchers to infiltrate our institutions and target our food supply, an act that could cripple our economy and endanger American lives," FBI Director Kash Patel told Fox News Digital in a statement. "Smuggling a known agroterrorism agent into the U.S. is not just a violation of law, it's a direct threat to national security. I commend the FBI Detroit Division and our partners at CBP for stopping this biological threat before it could do real damage."
The University of Michigan released a statement regarding the incident on Wednesday.
"As one of the world's leading public research institutions, the University of Michigan is dedicated to advancing knowledge, solving challenging problems and improving nearly every facet of the human experience. Our research enterprise across all three campuses is united in this commitment to serving the people of Michigan and the world," the school said.
"We strongly condemn any actions that seek to cause harm, threaten national security or undermine the university's critical public mission. It is important to note that the university has received no funding from the Chinese government in relation to research conducted by the accused individuals. We have and will continue to cooperate with federal law enforcement in its ongoing investigation and prosecution."
READ THE FULL AFFIDAVIT
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
ZEISS CLARUS 700 Receives NMPA Approval in China
ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 5, 2025 /CNW/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China, offering advanced retinal diagnostic capabilities with ultra-widefield, high-resolution images in True Color and unsurpassed quality. The fundus imaging device with Fluorescein Angiography helps eye care specialists in China unlock the full potential of their clinic's retina workflow to support improved patient vision preservation. "ZEISS CLARUS 700 represents a major step forward in retinal imaging," emphasizes Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. "By seamlessly integrating ultra-widefield Fluorescein Angiography (FA) imaging with true-color reproduction, this system delivers unprecedented clarity for comprehensive visualization from the macular region to the extreme retinal periphery, enhancing efficiency and supporting precise decision-making within the ZEISS Retina Workflow." "Integrating ultra-widefield imaging, unsurpassed clarity, and AI-enhanced capture, the CLARUS 700 redefines fundus angiography benchmarks. It will provide unparalleled diagnostic precision for Chinese doctors and unprecedented comfort for their patients," says Maxwell Liu, Head of Sales & Services at ZEISS Medical Technology China. Ultra-widefield fluorescein angiography serves as a highly valuable examination tool for assessing nonperfused retinal areas. The ZEISS CLARUS 700 HD ultra-widefield fundus imaging camera is an advanced retinal imaging system that provides True Color, high-resolution images. It captures 133°1 in a single image and up to 267° with multiple captures, offering detailed views of the retina. Equipped with both fluorescein angiography and live infrared imaging capabilities, the CLARUS 700 aids in diagnosing and monitoring retinal diseases2. Furthermore, the fundus imaging camera offers innovative technology features including PrecisionFocus for quickly seeing details in the regions of interest, QuickCompare to compare pathology changes observed in past patient visits, and AutoBright so ophthalmologists can spend more time analyzing images and less time adjusting them. More information about the CLARUS® 700 from ZEISS can be found here. 1 CLARUS 700#white-paper2 Xiao, Y., Dan, H., Du, X. et al. Assessment of early diabetic retinopathy severity using ultra-widefield Clarus versus conventional five-field and ultra-widefield Optos fundus imaging. Sci Rep 13, 17131 (2023). Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global Communications OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: View original content to download multimedia: SOURCE Carl Zeiss Meditec AG View original content to download multimedia:
Yahoo
12 hours ago
- Yahoo
Chinese scientist faces hearing after pathogen seized by FBI
(NewsNation) — A detention hearing was postponed on Thursday for Yunqing Jian, a Chinese scientist who was caught smuggling a pathogen into the U.S. last year. Jian and her boyfriend, Zunyong Liu, were charged by the FBI earlier this week with conspiracy, smuggling, making false statements and visa fraud. The FBI says Liu tried to sneak Fusarium graminearum into the country but was turned away and sent back to China after changing his story during an interrogation about red plant material discovered in his backpack. Unlicensed EMT indicted after allegedly caring for over 100 patients Jian and Liu had exchanged messages suggesting that Jian was already tending to the toxic fungus at a University of Michigan lab before Liu, a lab researcher at the university, was caught at the Detroit airport. The university does not have federal permits to handle it. The FBI acknowledged that a scientific journal described Fusarium graminearum as a potential 'agroterrorism weapon.' The pathogen is known to cause diseases in wheat, barley, maize and rice. The new court date has been announced for June 13. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.